Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Arch Therapeutics, Inc. ARTH OTC

Other OTC • Healthcare • Biotechnology • US • USD

SharesGrow Score
31/100
1/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Arch Therapeutics, Inc. (ARTH) — Analyst outlook / Analyst consensus target is. Based on 3 analyst ratings, the consensus is bullish — 3 Buy.

ARTH Analyst Ratings

Buy
3
Ratings
3 Buy
Based on 3 analysts giving stock ratings to Arch Therapeutics, Inc. in the past 3 months
Rating breakdown
Buy
3 100%
100%
Buy
3 analysts
0%
Hold
0 analysts
0%
Sell
0 analysts

People Also View

CMVLF
CMVLF
Cellectis S.A.
$3.08
-30.00%
 ATBPF
ATBPF
Antibe Therapeutics Inc.
$0.22
-0.19%
 AWKNF
AWKNF
Awakn Life Sciences Corp.
$0.07
+0.00%
 BCDAW
BCDAW
BioCardia, Inc.
$0.01
-3.17%
 BIOAF
BIOAF
Bioasis Technologies Inc.
$0.00
+0.00%
 AVXT
AVXT
AVAX Technologies, Inc.
$0.00
+0.00%
 ADYX
ADYX
Adynxx, Inc.
$0.00
+0.00%
 ADILW
ADILW
Adial Pharmaceuticals, Inc. WT EXP 073123
$0.00
-57.14%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message